John R. Hurst, MD, PhD, explains how BEAM-302 gene editing targets both lung and liver disease in alpha-1 antitrypsin deficiency.
John R. Hurst, MD, PhD
Advertisement
John R. Hurst, MD, PhD, is the pro vice provost of international health at University College London.
Articles by John R. Hurst, MD, PhD
Advertisement
Latest Updated Articles
One Treatment, Two Targets: BEAM-302 in AATD: John Hurst, MD, PhDSeptember 8th 2026
Advertisement
Advertisement
Trending on AJMC
1
Tavapadon for Parkinson Disease Approved by FDA
2
NCCN Journal Publishes Guidelines Update in Mantle Cell Lymphoma
3
Baricitinib Approved for Severe Alopecia Areata in Adolescents
4
Medicare Cap Eases Patient Costs as Negotiation Squeezes Practices
5